Can we cure indolent lymphomas?

Clinical Cancer Research

Volumn 3, Issue 12 II, 1997, Pages 2655-2659

  Cabanillas, Fernando ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; INTERFERON; PREDNISONE; PROTEIN BCL 2; TUMOR MARKER; VINCRISTINE;

BONE MARROW TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED STUDY; FOLLICULAR LYMPHOMA; HUMAN; LYMPHOMA; LYMPHOMA CELL; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CLINICAL PROTOCOLS; CLINICAL TRIALS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; HUMANS; INTERFERONS; LYMPHOMA; NEOPLASM STAGING; PREDNISONE; SURVIVAL ANALYSIS; VINCRISTINE;

EID: 0031431537     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (31)

1. Horning, S. Treatment approaches to the low-grade lymphomas. Blood, 83: 881-884, 1994.
2. MacManus, M. P., and Hoppe, R. T. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J. Clin. Oncol., 14: 1282-1290, 1996.
3. Paryani, S. B., Hoppe, R. T., Cox, R. S., Colby, T. V., Rosenberg, S. A., and Kaplan, H. S. Analysis of non-Hodgkin's lymphomas with nodular and favorable histologies, stage I and II. Cancer (Phila.), 52: 2300-2307, 1983.
4. McLaughlin, P., Fuller, L., Redman, J., Hagemeister, F., Durr, E., Allen, P., Holmes, L., Velasquez, W., Swan, F., and Cabanillas, F. Stage I-II low-grade lymphomas: a prospective trial of combination chemotherapy and radiotherapy. Ann. Oncol., 2: 137-140, 1991.
5. Gospodarowicz, M., Sutcliffe, S. B., and Brierly, J. D. Involved radiotherapy in clinical stage I-II low-grade lymphoma. In: Fifth International Conference on Malignant Lymphomas, p. 53. Lugano, Switzerland, 1993.
6. Richards, M. A., Gregory, W. M., and Hall, P. A. Management of localized non-Hodgkin's lymphoma: the experience at St. Bartholomew's Hospital, 1972-1985. Hematol. Oncol., 7: 1-18, 1989.
7. McLaughlin, P., Fuller, L. M., Velasquez, W. S., Sullivan-Halley, J. A., Butler, J., and Cabanillas, F. Stage I-II follicular Iymphoma. Treatment results for 76 patients. Cancer (Phila.), 58: 1596-1602, 1986.
8. McLaughlin, P., Fuller, L. M., and Velasquez, W. S. Stage III follicular lymphoma: durable remissions with a combined chemotherapy-radiotherapy regimen. J. Clin. Oncol., 5: 867-874, 1987.
9. Cox, J. D., Komaki, R., and Kun, L. E. Stage III nodular lymphoreticular tumors (non-Hodgkin's lymphoma): results of central lymphatic radiation. Cancer (Phila.), 47: 2247-2252, 1981.
10. McLaughlin, P., Cabanillas, F., Hagemeister, F. B., Swan, F., Jr., Romaguera, J. E., Taylor, S., Rodriguez, M. A., Velasquez, W. S., Redman, J. R., and Gutterman, J. U. CHOP-Bleo plus interferon for stage IV low-grade lymphoma. Ann. Oncol., 4: 205-211, 1993.
11. Smalley, R. V., Andersen, J. W., Hawkins, M. J., Bhide, V., O'Connell, M. J., Oken, M. M., and Borden, E. C. Interferon α combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma. N. Engl. J. Med., 327: 1336-1341, 1992.
12. Solal-Celigny, P., Lepage, E., Brousse, N., Reyes, F., Haioun, C., Leporrier, M., Peuchmaur, M., Bosly, A., Parlier, Y., Brice, P., Coiffer, B., and Gisselbrecht, C. Recombinant interferon α-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. N. Engl. J. Med., 329: 1608-1614, 1993.
13. Price, C. G. A., Rohatiner, A. Z. S., Steward, W., Deakin, D., Bailey, N., Norton, A., Blackledge, G., Crowther, D., and Lister, T. A. Interferon-α 2b in the treatment of follicular lymphoma: preliminary results of a trial in progress. Ann. Oncol., 2: 141-145, 1991.
14. Hagenbeek, A., Carde, P., Somers, R., Thomas, J., de Bock, R., Raemaekers, J., van Hoof, A., Glabbeke, M., and Meerwaldt, J. H. Maintenance of remission with human recombinant α-2 interferon (Roferon-A) in patients with stages III-IV low-grade malignant non-Hodgkin's lymphoma. Results from a prospective randomised Phase III clinical trial in 331 patients. Blood, 80: 288, 1992.
15. Tsujimoto, Y., Yunis, J., and Onorato-Showe, L. Molecular cloning of the chromosomal breakpoint of B cell lymphomas and leukemias with the t(11;14) chromosome translocation. Science (Washington DC), 224: 1403-1406, 1984.
16. Lee, M. S., Chang, K., Cabanillas, F., Freireich, E. J., Trujillo, J. M., and Stass, S. Detection of minimal residual cells carrying the t(14;18) by DNA sequence amplification. Science (Washington DC), 237: 175-178, 1987.
17. Price, C. G. A., Meerabux, J., Murtagh, S., and Cotter, F. E. The significance of circulating cells carrying the t(14;18) in patients in long-term remission from follicular lymphoma. J. Clin. Oncol., 9: 1527-1532, 1991.
18. Gribben, J., Freedman, A., Woo, S. D., Blake, K., Shu, R. S., Freeman, G., Longtine, J. A., Pinkus, G. S., and Nadler, L. M. All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of BCL-2 have residual cells containing the BCL-2 rearrangement at evaluation and after treatment. Blood, 78: 3275-3280, 1992.
19. H rearrangements in benign lymphoid tissues with follicular hyperplasia. Oncogene, 6: 2271-2276, 1991.
20. Dolken, G., Illerhaus, G., Hirt, C., and Mertelsmann, R. Bcl-2/JH rearrangements in circulating B cells of healthy blood donors and patients with non-malignant diseases. J. Clin. Oncol., 14: 1333-1344, 1996.
21. Gribben, J. G., Neuberg, D., and Freedman, A. Detection by PCR of residual cells with the BCL-2 translocation after autologous bone marrow transplantation for B cell lymphoma predicts for relapse. Blood, 87: 3449-3457, 1993.
22. Gribben, J. Attainment of molecular remission: a worthwhile goal? J. Clin. Oncol., 12: 1532-1534, 1994.
23. Gribben, J. G., Neuberg, D., Barber, M., Moore, J., Pesek, K. W., Freedman, A. S., and Nadler, L. M. Detection of residual lymphoma cells by polymerase chain reaction in peripheral blood is significantly less predictive for relapse than detection in bone marrow. Blood, 83: 3800-3807, 1994.
24. Gribben, J. G., Freedman, A. S., and Nadler, L. M. Minimal disease and purging in lymphoma. In: Advances and Controversies in Bone Marrow Transplantation, p. 56. Keystone, CO: New York Liss, 1994.
25. Johnson, P. W. M., Price, C. G. A., Smith, T., Cotter, F. E., Meerabux, J., Rohatiner, A. Z. S., Young, B. D., and Lister, T. A. Detection of cells bearing the t(14;18) translocation following myeloablative treatment and autologous bone marrow transplantation for follicular lymphoma. J. Clin. Oncol., 12: 798-805, 1994.
26. McLaughlin, P., Hagemeister, F. B., Swan, F., Cabanillas, F., Romaguera, J., Rodriguez, M. A., Lee, M. S., Pate, O., Sarris, A., and Younes, A. Intensive conventional dose chemotherapy for stage IV low-grade lymphoma: high remission rates and reversion to negative of peripheral blood bcl-2 rearrangement. Ann. Oncol., 5: S73-S77, 1994.
27. McLaughlin, P., Hagemeister, F. B., Romaguera, J. E., Sarris, A. H., Pate, O., Younes, A., Swan, F., Keating, M., and Cabanillas, F. Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma. J. Clin. Oncol., 14: 1262-1268, 1996.
28. Cabanillas, F., Lee, M. S., McLaughlin, P., Hagemeister, F. B., Cox, J. D., Rodriguez, M. A., Ha, C. S., Romaguera, J. E., Sarris, A., and Younes, A. Early achievement of molecular complete remission (CR) assayed by PCR predicts for failure-free survival in low-grade follicular lymphomas. Blood, 86: 604a, 1995.
29. Tsujimoto, Y., Cossman, J., and Jaffe, E. Involvement of the BCL-2 gene in human follicular lymphoma. Science (Washington DC), 228: 1440-1443, 1985.
30. Cleary, M., Galili, N., and Sklar, J. Detection of a second t(14;18) breakpoint cluster region in human follicular lymphomas. J. Exp. Med., 164: 315, 1986.
31. Lopez-Guillermo, A., Lee, M., Pugh, W., McLaughlin, P., and Cabanillas, F. The molecular breakpoint site of bcl-2 gene has prognostic importance in indolent follicular lymphoma (FL). Blood, 88: 203a, 1996.